2022 -- S 2870 | |
======== | |
LC005392 | |
======== | |
STATE OF RHODE ISLAND | |
IN GENERAL ASSEMBLY | |
JANUARY SESSION, A.D. 2022 | |
____________ | |
S E N A T E R E S O L U T I O N | |
PROCLAIMING MAY 1ST THROUGH MAY 8TH TO BE "TARDIVE DYSKINESIA (TD) | |
AWARENESS WEEK" IN THE STATE OF RHODE ISLAND | |
| |
Introduced By: Senator Joshua Miller | |
Date Introduced: April 12, 2022 | |
Referred To: Recommended for Immediate Consideration | |
1 | WHEREAS, Many people with serious, chronic mental illness, such as schizophrenia, |
2 | bipolar disorder, severe depression, or gastrointestinal disorders, including gastroparesis, nausea, |
3 | and vomiting require treatment with medications that work as dopamine receptor blocking agents |
4 | (DRBAs), including antipsychotics; and |
5 | WHEREAS, While ongoing treatment with these medications can be very helpful, and |
6 | even lifesaving, for many people, it can also lead to Tardive Dyskinesia (TD); and |
7 | WHEREAS, Tardive Dyskinesia is a movement disorder that is characterized by random, |
8 | involuntary, and uncontrolled movements of different muscles in the face, trunk and extremities; |
9 | and |
10 | WHEREAS, Tardive Dyskinesia can develop months, years, or decades after a person |
11 | starts taking DRBAs and even after they have discontinued use of those medications. Not |
12 | everyone who takes a DRBA develops TD, but if it develops it is often permanent; and |
13 | WHEREAS, It is estimated that over 600,000 Americans suffer from Tardive Dyskinesia. |
14 | According to the National Alliance for Mental Illness, one in every four patients receiving long- |
15 | term treatment with an antipsychotic medication will experience Tardive Dyskinesia; and |
16 | WHEREAS, Years of difficult and challenging research have resulted in recent scientific |
17 | breakthroughs, with two new treatments for Tardive Dyskinesia approved by the United States |
18 | Food and Drug Administration; and |
19 | WHEREAS, Tardive Dyskinesia is often unrecognized and patients suffering from the |
| |
1 | illness are commonly misdiagnosed. Regular screening for TD in patients taking DRBA |
2 | medications is recommended by the American Psychiatric Association (APA); now, therefore be |
3 | it |
4 | RESOLVED, That this Senate of the State of Rhode Island hereby proclaims May 1st |
5 | through May 8th to be "Tardive Dyskinesia (TD) Awareness Week" in the State of Rhode Island; |
6 | and be it further |
7 | RESOLVED, That this Senate hereby encourages the medical community and all |
8 | individuals in the United States and Rhode Island to become better informed about and aware of |
9 | Tardive Dyskinesia; and be it further |
10 | RESOLVED, That the Secretary of State be and hereby is authorized and directed to |
11 | transmit a duly certified copy of this resolution to Ms. Karla M. Kiriako, Director, State |
12 | Government Affairs-East, Neurocrine Biosciences, Inc. |
======== | |
LC005392 | |
======== | |
| LC005392 - Page 2 of 2 |